Virus Therapy Reality or Myth?

After having been the next best thing to sliced bread during the first and second AIDS media hype, virus therapy companies are again in the focus of venture capital investors.

This nowadays especially applies to HIV, Influenza A (IAV) and Hepatitis C treatments for which might or might not be a mass market.

A new one in our neck of the woods (sorry, german only):

Alfred Wieder AG – MIG Beteiligung an Vidologik

Alfred Wieder AG – MIG Beteiligung Virologik Kooperationspartner von FORIGEN

Is this all the next wave of hype or are current developments leading somewhere?

The material in this press release comes from the originating research organization. Content may be edited for style and length. Want more? Sign up for our daily email.